Active Ingredient History
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The most potent are members of the genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of LSD, mescaline, and DMT. In general, the effects include euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 2)
Alzheimer Disease (Early Phase 1)
Amnesia (Phase 1)
Amphetamine-Related Disorders (Phase 1/Phase 2)
Anorexia Nervosa (Phase 2)
Anxiety (Phase 2)
Binge-Eating Disorder (Phase 2)
Bipolar Disorder (Phase 2)
Body Dysmorphic Disorders (Phase 2)
Burnout, Professional (Phase 1/Phase 2)
Burnout, Psychological (Phase 1/Phase 2)
Caregiver Burden (Phase 1/Phase 2)
Central Nervous System Agents (Phase 1)
Cluster Headache (Phase 1/Phase 2)
Cocaine-Related Disorders (Phase 2)
Cognitive Dysfunction (Early Phase 1)
COVID-19 (Phase 1/Phase 2)
Demoralization (Phase 2)
Depression (Phase 2)
Depressive Disorder, Major (Phase 2)
Depressive Disorder, Treatment-Resistant (Phase 2)
Fibromyalgia (Phase 2)
Grief (Phase 1)
Hallucinogens (Phase 1)
Headache (Phase 1)
Healthy Volunteers (Phase 2)
Hospices (Phase 2)
Melanoma (Phase 2)
Migraine Disorders (Phase 2)
Neoplasms (Phase 2)
Obsessive Behavior (Phase 2)
Obsessive-Compulsive Disorder (Phase 1/Phase 2)
Opioid-Related Disorders (Phase 1)
Parkinson Disease (Phase 2)
Perception (Phase 1)
Pharmacologic Actions (Phase 1)
Post-Traumatic Headache (Phase 1)
Psilocybin (Phase 2)
Psychological Distress (Phase 1/Phase 2)
Psychotherapy (Phase 2)
Psychotropic Drugs (Phase 1)
Religion (Phase 1)
Stress Disorders, Post-Traumatic (Phase 1/Phase 2)
Terminally Ill (Phase 2)
Therapeutic Uses (Phase 1)
Visual Pathways (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue